DWM
SRPT icon

Dynasty Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Dynasty Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$232K Sell
12,909
-896
-6% -$16.9K ﹤0.01% 344
2026
Q1 		$300K Buy
13,805
+1,522
+12% +$29.5K ﹤0.01% 290
2025
Q4 		$264K Sell
12,283
-2,050
-14% -$43.2K ﹤0.01% 304
2025
Q3 		$276K Buy
+14,333
New +$256K ﹤0.01% 270

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Dynasty Wealth Management's SRPT Position: Q2 2026 in Review

Dynasty Wealth Management reduced its Sarepta Therapeutics (SRPT) stake by 6.5% in Q2 2026, selling an estimated $16.9K and leaving 12,909 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #344.

Dynasty Wealth Management first reported a position in SRPT in Q3 2025 and has held it in 4 quarters since. The position peaked at $300K in Q1 2026. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Dynasty Wealth Management held 12,909 shares of Sarepta Therapeutics worth $232K as of Q2 2026.
  • Dynasty Wealth Management sold 896 Sarepta Therapeutics shares in Q2 2026, an estimated $16.9K.
  • Sarepta Therapeutics made up ﹤0.01% of Dynasty Wealth Management's portfolio in Q2 2026, its #344 holding.
  • Dynasty Wealth Management first reported a position in Sarepta Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Dynasty Wealth Management's Sarepta Therapeutics position peaked at $300K in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Dynasty Wealth Management's 13F filing for Q2 2026, filed 13 Aug 2026.